Biogen Inc. (BIIB) vs Bristol Myers Squibb Company (BMY)
Biogen Inc. and Bristol Myers Squibb Company are both Drug Manufacturers General companies. Bristol Myers Squibb Company is the larger, with a market value of $125.9B against $33.5B — 3.8× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.8× against 40.1×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 3.11% against 0.31%. Bristol Myers Squibb Company has the higher net margin (18.9% vs 8.32%) and the higher return on invested capital (13.7% vs 3.11%). Across the 22 metrics below, Bristol Myers Squibb Company leads on 16 and Biogen Inc. on 6.
Valuation
Profitability
| Metric | BIIB | BMY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 73.99% | 70.16% | 72.77% |
| Operating margin | 12.35% | 24.22% | 18.90% |
| Net margin | 8.32% | 18.87% | 8.27% |
| Free cash flow margin | 25.33% | 23.26% | 17.25% |
| Return on equity | 4.58% | 46.63% | 6.97% |
| Return on assets | 2.76% | 10.18% | 2.76% |
| Return on invested capital | 3.11% | 13.69% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack